| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,947 |
14,487 |
$2.39M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
11,148 |
11,043 |
$2.24M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
10,689 |
10,358 |
$544K |
| 99215 |
Prolong outpt/office vis |
2,138 |
2,080 |
$356K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,388 |
3,339 |
$344K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,532 |
1,516 |
$180K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,527 |
1,492 |
$167K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,295 |
3,271 |
$125K |
| 87631 |
|
581 |
579 |
$99K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
438 |
328 |
$22K |
| 87807 |
|
1,385 |
1,344 |
$19K |
| 87428 |
|
263 |
258 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
588 |
294 |
$9K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
120 |
112 |
$8K |
| 81003 |
|
2,988 |
2,941 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
341 |
337 |
$7K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
207 |
198 |
$6K |
| 81025 |
|
571 |
561 |
$5K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
160 |
132 |
$5K |
| 99205 |
Prolong outpt/office vis |
15 |
15 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
220 |
202 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
167 |
166 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
141 |
138 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
31 |
30 |
$1K |
| 99000 |
|
336 |
331 |
$892.13 |
| 0012A |
|
31 |
30 |
$738.14 |
| 0011A |
|
39 |
38 |
$542.08 |
| 0001A |
|
14 |
14 |
$220.22 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
16 |
16 |
$35.10 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
110 |
109 |
$18.99 |
| 94760 |
|
230 |
223 |
$3.92 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
13 |
13 |
$0.00 |